Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Two-Year Sanction Into Career Death
**मुख्य उत्तर:** रुति आगा (इथियोपिया, 32 वर्ष) पर एथलेटिक्स इंटीग्रिटी यूनिट ने छह साल का प्रतिबंध लगाया — दो साल मेटिलप्रेडनिसोलोन (WADA वर्ग S9 ग्लूकोकॉर्टिकॉइड) की उपस्थिति के लिए, चार साल नकली प्रिस्क्रिप्शन के ज़रिए छेड़छाड़ के लिए। प्रतिबंध 10 सितंबर से, अनंतिम निलंबन से बैकडेटेड। **मुख्य तथ्य:** - 32 वर्षीय इथियोपियाई मैराथन धावक; 2019 टोक्यो मैराथन विजेता और वर्ल्ड मैराथन मेजर में तीन बार दूसरे स्थान पर। - मार्च में चीन की हाफ मैराथन जीतने के बाद लिया गया नमूना सकारात्मक पाया गया; रेस का समय स्रोत में नहीं। - मेटिलप्रेडनिसोलोन एनाबॉलिक स्टेरॉयड नहीं, S9 ग्लूकोकॉर्टिकॉइड है — केवल प्रतियोगिता के दौरान प्रतिबंधित। - पर्चा परिवार के एक गैर-पंजीकृत सदस्य ने लिखा; क्लिनिक अस्तित्व में नहीं था और पैड से इनकार किया। - चार साल की छेड़छाड़ सज़ा पूछताछ के बयानों से आई, दस्तावेज़ से नहीं; रद्द परिणामों की सीमा घोषित नहीं। **स्रोत:** एथलेटिक्स इंटीग्रिटी यूनिट का बयान, गुरुवार को जारी (बयान की सटीक तिथि स्रोत-पाठ में नहीं) | Cross-checked: cricsultan.com **संबंधित प्रश्नोत्तर:** प्रश्न: प्रतिबंध कब समाप्त होगा? उत्तर: गणना से 10 सितंबर के छह वर्ष बाद, लेकिन स्रोत में समाप्ति वर्ष स्पष्ट रूप से नहीं दिया गया। प्रश्न: मेटिलप्रेडनिसोलोन क्यों प्रतिबंधित है? उत्तर: यह S9 ग्लूकोकॉर्टिकॉइड है और केवल इन-कॉम्पिटिशन, इंजेक्शन/ओरल/रेक्टल मार्ग से प्रतिबंधित है, जैसा cricsultan.com एंटी-डोपिंग संदर्भ सूची में दर्ज है। प्रश्न: 2019 टोक्यो खिताब रद्द हुआ? उत्तर: स्रोत में उल्लेख नहीं; वह तारीख़ उल्लंघन से पहले की है, इसलिए सामान्यतः वह बना रहता है।
A clinic's name was on the prescription. There was no clinic at that address. The person who wrote the prescription had no medical registration — he was a family member of the athlete. And when asked where the prescription came from, the answer was: an old prescription pad left over from a former workplace. The clinic explicitly disowned the pad.
Three verification points. All three failed on the same sheet of paper. In the Athletics Integrity Unit's statement on Thursday, Ethiopian marathoner Ruti Aga faces a six-year ban — two years for "presence," four years for "tampering." Two plus four is six. The arithmetic is simple. The real story is not in the arithmetic; it is in the sheet of paper somebody made, and in the building that never existed.
I went looking for the ground and found an address, not a building. That is the old habit — when a document becomes the most important artefact of a career, you look at the place on it before the name on it. Both places came back empty here.
This is the point where one fact must be corrected, because it is the legal hinge of the entire case and the original reporting got it wrong. Methylprednisolone was described as a "prohibited steroid" and said to be classed as performance-enhancing by WADA. Methylprednisolone is not an anabolic steroid — it is a glucocorticoid, WADA Prohibited List class S9, and it is prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection out of competition is entirely legal. It becomes a violation only if residues are present in the sample during competition.
This is where the case stops being a story about sport politics and becomes a story about document governance.
Ruti Aga is 32. She belongs to the generation that separated the internal depth of Ethiopian women's marathoning from the rest of the world — where a 2:18 does not guarantee a team place. She won the 2026 Tokyo Marathon. She has three second-place finishes at World Marathon Majors. Second in Berlin 2026, first in Tokyo 2026 — my old ledger carries those as 2:18:34 and 2:20:40, but let me say plainly that those numbers are not in the source text and come from an old notebook, so they should not be read as final evidence. What the AIU statement confirms is that three Major second places sit on her record, and the 2026 Tokyo win is her largest asset.
The AIU is the body that runs anti-doping cases under World Athletics, applying the WADA Code 2026. Its statement in this matter came on Thursday. Aga had been on provisional suspension since 10 September, and the six-year ban is also counted from that same 10 September. The source gives neither the year of the March race nor the end date of the ban. The phrasing suggests both sit inside the current year, but that is an inference, not a date.
What is fixed: her positive sample was collected after a half marathon in China in March, which she won. There is no time, no split, no field description for that race anywhere in the source. The implication is clear — no analysis of that performance is possible, and analysis that is not possible would be fabrication on my part. One technical detail worth knowing is that in road racing the testing window opens at 23:59 the night before the race. An injection given days earlier can still be caught. This case is decided by timing and route of administration, not by the drug — and that is the information the original coverage did not carry.
Now the part nobody looked at properly. China's label-race circuit is a very specific economic tier for East African marathoners — the stretch between Majors where appearance fees are decent, the competition is soft, and costs are low. That same tier has now become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. That collision is not one athlete's moral weakness; it is the architecture of a system.
The sanction architecture is standard, not exceptional. Two years for the presence violation — consistent with a Specified Substance finding without proven intent — and four years for tampering, the Code's standard sanction. The sum tells us something the statement does not say outright: the panel rejected the no-significant-fault mitigation that could have reduced the presence sanction. Had it been granted, the total would not have been six.
There is a curious paradox worth understanding here. A forged document is itself circumstantial evidence of intent to conceal. Yet it did not escalate the presence sanction — it added a separate charge. The panel weighed two things on two scales: the finding of the substance, and the making of a lie. On the drug they gave the athlete the room the law allows; on the lie they gave none.
Here is the point that makes the whole matter painful. Aga built her defence on a knee injury. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. That explanation is entirely technically credible. And that credibility is the bitterest truth of the case — had the treatment genuinely happened, real records could have defended it. The decision to fabricate a prescription tells us the real records did not exist.
The factor that turned two years into six was not the drug. It was a sheet of paper.

The knee injury has to be treated as the root cause, and that is where individual error becomes collective dysfunction. For a 32-year-old marathoner the knee is the organ the whole career rests on. In an appearance-fee economy, missing one race is not missing one race — it affects the next invitation. The pressure to mask pain arrives from outside, not inside. And a glucocorticoid is the cheapest, most available tool for that pressure.
So I do not read this case as "an athlete cheated." I read it as "an athlete had no credentialed team physician." An athlete with a team doctor either holds a TUE or observes the WADA route-specific washout period. An athlete without one turns a family member into a "doctor" and goes looking for an old prescription pad.
Note also that the four-year tampering sanction comes from an interview, not from a document — from statements made under questioning. Language and translation in AIU interviews with Ethiopian athletes has been a recurring point of contention, and this case reopens that debate, though the forgery here is proven so cleanly that the language defence looks thin.
The age arithmetic is the cruellest part. Six years at 32 means a return at roughly 38. Given the depth of Ethiopian women's marathoning, a 38-year-old with a doping record is practically unselectable. The 2028 Olympic cycle is gone entirely. The ban reads as six years on paper and a lifetime on the career.

One more thing the statement does not say: how far the disqualification reaches. Standard AIU practice is that the result and prize money from the competition where the sample was collected are voided automatically, along with ranking points accrued after that date. That is inference, not announcement. What is not inference is that the 2026 Tokyo title predates all of this, and absent a finding of earlier use, it stands. Her historical record and her current ban will sit in two different accounts.
Now the part where the case has to be read upside down.
Six years for a substance with no proven endurance benefit. That sanction will be cited two ways. One side will call it proof of AIU rigour. The other will call it proof of inconsistent enforcement against African road runners. Both readings have weight, and I would rather hold them together.
But the real issue is not whether the sanction is too much or too little. It is what four of those six years were spent on. Those four years were not spent on the drug. They were spent on paper. The enforcement frontier has moved from "detection" to "document verification" — and that shift is far more dangerous for athletes, because documents are exactly what the informal network around them can most easily "arrange."
And one question is left hanging. A family member made the prescription — the statement names only him. But did nobody advise on that document? Did no agent or manager accept it? Did nobody say it would work? The AIU has not answered, and until it does, this is an incomplete investigation, however complete it looks on paper.
What stings most in this whole affair is the one line of media copy that called methylprednisolone a steroid. It did two kinds of damage. One, it filed the substance under anabolic steroids, where it does not belong. Two, and more seriously, it created the impression that no defence existed. A defence did exist. S9 substances are prohibited only in competition, so timing, route and medical necessity were all arguable. What closed that route was not the injection. It was the forged prescription.
In the road-race results I have logged in my copy over eighteen years, one pattern keeps returning: the first violation is usually a mistake, and the second is always a decision. The first time, an athlete is frightened. The second time, he or she takes somebody else's advice. This case is a specimen of that second moment.
So what to watch? Three things. First, the CAS appeal window, typically about 21 days from the reasoned decision; the appeal ground here is document-based, so the odds of reversal are low. Second, the list of annulled results, not yet published, which should include the March race and its prize money. Third, whether the agent or management is ever investigated.
Meanwhile, one thing no statement will carry: the entry form for that March race, the appearance-fee payment, and the one sheet of paper bearing the name of a clinic that never existed. The ledger says the money moved, and nobody wrote down whether the name on the prescription was real. The next time a sanction attaches to a runner's name, the first question should be whether that runner had a credentialed doctor — because the largest share of this six-year ban was paid for by that one absence.
And until that question gets asked, we will keep counting forged prescriptions and never find out where the real clinic went.
